MX2017002968A - Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular. - Google Patents

Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular.

Info

Publication number
MX2017002968A
MX2017002968A MX2017002968A MX2017002968A MX2017002968A MX 2017002968 A MX2017002968 A MX 2017002968A MX 2017002968 A MX2017002968 A MX 2017002968A MX 2017002968 A MX2017002968 A MX 2017002968A MX 2017002968 A MX2017002968 A MX 2017002968A
Authority
MX
Mexico
Prior art keywords
monoclonal antibody
humanized monoclonal
lipase
inhibit
enzymatic activity
Prior art date
Application number
MX2017002968A
Other languages
English (en)
Other versions
MX388559B (es
Inventor
Naito Shoichi
Yamane Shoji
Aino Hiroaki
Nakamura Etsuo
Imai Sunao
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55459146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017002968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2017002968A publication Critical patent/MX2017002968A/es
Publication of MX388559B publication Critical patent/MX388559B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal humanizado, o un fragmento del mismo, que inhibe de manera selectiva la actividad enzimática de la lipasa endotelial vascular, y composiciones farmacéuticas que contienen a los mismos como ingrediente activo, útiles para el tratamiento de la arterioesclerosis o el síndrome metabólico.
MX2017002968A 2014-09-11 2015-09-10 Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular. MX388559B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014184710 2014-09-11
PCT/JP2015/075668 WO2016039402A1 (ja) 2014-09-11 2015-09-10 血管内皮リパーゼの酵素活性を阻害するヒト化モノクローナル抗体

Publications (2)

Publication Number Publication Date
MX2017002968A true MX2017002968A (es) 2017-06-15
MX388559B MX388559B (es) 2025-03-20

Family

ID=55459146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002968A MX388559B (es) 2014-09-11 2015-09-10 Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular.

Country Status (18)

Country Link
US (2) US10570215B2 (es)
EP (1) EP3192813A4 (es)
JP (2) JP6635599B2 (es)
KR (1) KR102520286B1 (es)
CN (1) CN107074963B (es)
AR (1) AR101811A1 (es)
AU (1) AU2015313179B2 (es)
CA (1) CA2960994C (es)
CL (1) CL2017000595A1 (es)
EA (1) EA036324B1 (es)
IL (1) IL250981B (es)
MX (1) MX388559B (es)
MY (1) MY181835A (es)
PH (1) PH12017500461B1 (es)
SG (2) SG10201900605SA (es)
TW (2) TWI734410B (es)
WO (1) WO2016039402A1 (es)
ZA (1) ZA201702489B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3316909T (pt) * 2015-06-30 2023-11-22 Seattle Genetics Inc Anticorpos anti-ntb-a e composições e métodos relacionados
AU2018298676A1 (en) * 2017-07-10 2019-12-19 Innate Pharma Siglec-9-neutralizing antibodies
WO2019091449A1 (zh) * 2017-11-10 2019-05-16 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
JP7692411B2 (ja) * 2019-11-07 2025-06-13 メディミューン，エルエルシー 心血管疾患の治療用の内皮リパーゼ抗体
EP4110290A4 (en) * 2020-02-24 2024-06-05 Medimmune, LLC ANTI-ENDOTHELIAL LIPASE ANTIBODY FORMULATIONS
US20240092897A1 (en) * 2020-11-05 2024-03-21 Shanghai Jmt-Bio Technology Co., Ltd. Anti-siglec-15 antibody and application thereof in preparing drug
WO2025111317A1 (en) * 2023-11-21 2025-05-30 The Brigham And Women's Hospital, Inc. Klrb1 binding agents and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062075B2 (ja) * 1988-04-30 1994-01-12 大日本製薬株式会社 抗ヒトポストヘパリンプラズマ由来リポ蛋白リパーゼモノクローナル抗体およびその製造方法
ATE291080T1 (de) * 1996-12-06 2005-04-15 Aventis Pharma Inc Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
AU1941899A (en) 1997-12-19 1999-07-12 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use
NZ531180A (en) 1999-03-26 2005-06-24 Aventis Pharma Inc Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide
US9296825B2 (en) * 2011-10-12 2016-03-29 Shionogi & Co., Ltd. Monoclonal antibody against EL which inhibits enzyme activity of EL
WO2014142182A1 (ja) * 2013-03-14 2014-09-18 塩野義製薬株式会社 血管内皮リパーゼの酵素活性を阻害するモノクローナル抗体

Also Published As

Publication number Publication date
JP6635599B2 (ja) 2020-01-29
AU2015313179A1 (en) 2017-03-30
ZA201702489B (en) 2018-08-29
CL2017000595A1 (es) 2017-11-03
IL250981A0 (en) 2017-04-30
JPWO2016039402A1 (ja) 2017-06-22
JP2020059743A (ja) 2020-04-16
EP3192813A4 (en) 2018-08-01
US11136411B2 (en) 2021-10-05
PH12017500461A1 (en) 2017-07-31
CN107074963A (zh) 2017-08-18
PH12017500461B1 (en) 2023-07-19
TW201613982A (en) 2016-04-16
TWI734410B (zh) 2021-07-21
US10570215B2 (en) 2020-02-25
SG10201900605SA (en) 2019-02-27
US20200071424A1 (en) 2020-03-05
CA2960994C (en) 2025-07-08
CN107074963B (zh) 2021-07-16
WO2016039402A1 (ja) 2016-03-17
EA201790590A1 (ru) 2017-08-31
JP6827255B2 (ja) 2021-02-10
KR20170052655A (ko) 2017-05-12
AU2015313179B2 (en) 2020-10-22
KR102520286B1 (ko) 2023-04-10
EA036324B1 (ru) 2020-10-27
TWI688575B (zh) 2020-03-21
MY181835A (en) 2021-01-08
SG11201701762VA (en) 2017-04-27
TW202026313A (zh) 2020-07-16
BR112017004429A2 (pt) 2018-02-27
EP3192813A1 (en) 2017-07-19
IL250981B (en) 2020-06-30
CA2960994A1 (en) 2016-03-17
MX388559B (es) 2025-03-20
US20170260290A1 (en) 2017-09-14
AR101811A1 (es) 2017-01-11

Similar Documents

Publication Publication Date Title
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
MX2017002968A (es) Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
KR102609396B9 (ko) Ldha의 발현을 억제하기 위한 방법 및 조성물
IL283168A (en) Compositions and methods of modulating short-chain dehydrogenase activity
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
MX2017001976A (es) Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano.
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
EA201691421A1 (ru) Гетероарилы и их применение
MX2016011072A (es) Derivado de pirazol amida.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX391141B (es) Anticuerpos anti-ceramida.
IL282021A (en) Compounds and compositions for treating conditions associated with apj receptor activity
TR201907044T4 (tr) Yeni bileşikler.
EP3643302C0 (en) COMPOSITION COMPRISING A SESQUITERPENE DERIVATIVE AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF MUSCULAR DISEASES
PH12015502092A1 (en) Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
UY36922A (es) Inhibidores de asgr
EA202090453A3 (ru) Антитела к cd40
EP3593796C0 (en) COMPOSITION FOR THE TOPICAL TREATMENT OF SEVERE ACNE
AR106572A1 (es) Inhibidores de asgr
EA201991135A1 (ru) Комбинированная терапия ингибиторами аргиназы
EA201401235A1 (ru) Композиция, содержащая глюкозамин, фруктобарат кальция и витамин d для лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов, её применение и способ лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов и позвоночника